;PMID: 3038518
;source_file_2927.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..31] = [t:0..31]
;1)sentence:[e:37..138] = [t:37..138]
;2)section:[e:142..186] = [t:142..186]
;3)sentence:[e:190..300] = [t:190..300]
;4)sentence:[e:301..407] = [t:301..407]
;5)sentence:[e:408..531] = [t:408..531]
;6)sentence:[e:532..716] = [t:532..716]
;7)sentence:[e:717..788] = [t:717..788]
;8)sentence:[e:789..902] = [t:789..902]
;9)sentence:[e:903..1015] = [t:903..1015]
;10)sentence:[e:1016..1133] = [t:1016..1133]
;11)sentence:[e:1134..1325] = [t:1134..1325]
;12)sentence:[e:1326..1431] = [t:1326..1431]
;13)section:[e:1435..1479] = [t:1435..1479]

;section 0 Span:0..31
;EMBO J.  1987 May;6(5):1339-44.
(SEC
  (FRAG (NN:[0..4] EMBO) (NNP:[5..6] J) (.:[6..7] .) (CD:[9..13] 1987)
        (NNP:[14..17] May) (::[17..18] ;) (CD:[18..19] 6) (-LRB-:[19..20] -LRB-)
        (CD:[20..21] 5) (-RRB-:[21..22] -RRB-) (::[22..23] :)
        (CD:[23..30] 1339-44) (.:[30..31] .)))

;sentence 1 Span:37..138
;Characterization of a cell type-specific enhancer found in the human
;papilloma  virus type 18 genome.
(SENT
  (NP-HLN
    (NP (NN:[37..53] Characterization))
    (PP (IN:[54..56] of)
      (NP
        (NP (DT:[57..58] a)
          (ADJP
            (NML (NN:[59..63] cell) (NN:[64..68] type))
            (HYPH:[68..69] -) (JJ:[69..77] specific))
          (NN:[78..86] enhancer))
        (VP (VBN:[87..92] found)
          (NP (-NONE-:[92..92] *))
          (PP-LOC (IN:[93..95] in)
            (NP (DT:[96..99] the) (JJ:[100..105] human)
                (NN:[106..115] papilloma) (NN:[117..122] virus)
              (NML (NN:[123..127] type) (CD:[128..130] 18))
              (NN:[131..137] genome))))))
    (.:[137..138] .)))

;section 2 Span:142..186
;Swift FV, Bhat K, Younghusband HB, Hamada H.
(SEC
  (FRAG (NNP:[142..147] Swift) (NNP:[148..150] FV) (,:[150..151] ,)
        (NNP:[152..156] Bhat) (NNP:[157..159] K,) (NNP:[160..172] Younghusband)
        (NNP:[173..175] HB) (,:[175..176] ,) (NNP:[177..183] Hamada)
        (NNP:[184..185] H) (VBD:[185..186] .)))

;sentence 3 Span:190..300
;We have previously isolated long-range acting enhancer elements from the HeLa
; genome by functional selection.
(SENT
  (S
    (NP-SBJ (PRP:[190..192] We))
    (VP (VBP:[193..197] have)
      (ADVP-TMP (RB:[198..208] previously))
      (VP (VBN:[209..217] isolated)
        (NP
          (NP
            (ADJP
              (NML (JJ:[218..222] long) (HYPH:[222..223] -)
                   (NN:[223..228] range))
              (VBG:[229..235] acting))
            (NN:[236..244] enhancer) (NNS:[245..253] elements))
          (PP (IN:[254..258] from)
            (NP (DT:[259..262] the) (NN:[263..267] HeLa) (NN:[269..275] genome))))
        (PP-MNR (IN:[276..278] by)
          (NP (JJ:[279..289] functional) (NN:[290..299] selection)))))
    (.:[299..300] .)))

;sentence 4 Span:301..407
;In this report, the structural and functional  characteristics of one (GA1)
;of the enhancers are reported.
(SENT
  (S
    (PP (IN:[301..303] In)
      (NP (DT:[304..308] this) (NN:[309..315] report)))
    (,:[315..316] ,)
    (NP-SBJ-2
      (NP
        (NP (DT:[317..320] the) (JJ:[321..331] structural)
          (NML-1 (-NONE-:[331..331] *P*)))
        (CC:[332..335] and)
        (NP (JJ:[336..346] functional)
          (NML-1 (NNS:[348..363] characteristics))))
      (PP (IN:[364..366] of)
        (NP
          (NP (CD:[367..370] one)
            (PRN (-LRB-:[371..372] -LRB-)
              (NP (NN:[372..375] GA1))
              (-RRB-:[375..376] -RRB-)))
          (PP (IN:[377..379] of)
            (NP (DT:[380..383] the) (NNS:[384..393] enhancers))))))
    (VP (VBP:[394..397] are)
      (VP (VBN:[398..406] reported)
        (NP-2 (-NONE-:[406..406] *))))
    (.:[406..407] .)))

;sentence 5 Span:408..531
;By cloning various  restriction fragments and by deletion mutagenesis, the
;activity of GA1 was  located in a 230-bp region.
(SENT
  (S
    (PP-MNR
      (PP (IN:[408..410] By)
        (S-NOM
          (NP-SBJ (-NONE-:[410..410] *))
          (VP (VBG:[411..418] cloning)
            (NP (JJ:[419..426] various) (NN:[428..439] restriction)
                (NNS:[440..449] fragments)))))
      (CC:[450..453] and)
      (PP (IN:[454..456] by)
        (NP (NN:[457..465] deletion) (NN:[466..477] mutagenesis))))
    (,:[477..478] ,)
    (NP-SBJ-1
      (NP (DT:[479..482] the) (NN:[483..491] activity))
      (PP (IN:[492..494] of)
        (NP (NN:[495..498] GA1))))
    (VP (VBD:[499..502] was)
      (VP (VBN:[504..511] located)
        (NP-1 (-NONE-:[511..511] *))
        (PP (IN:[512..514] in)
          (NP (DT:[515..516] a)
            (NML (CD:[517..520] 230) (HYPH:[520..521] -) (NN:[521..523] bp))
            (NN:[524..530] region)))))
    (.:[530..531] .)))

;sentence 6 Span:532..716
;The nucleotide sequence of GA1 and genomic Southern  blot analysis indicated
;that GA1 is derived from human papilloma virus (HPV) 18  DNA that had been
;integrated into the HeLa genome.
(SENT
  (S
    (NP-SBJ
      (NP (DT:[532..535] The) (NN:[536..546] nucleotide)
          (NN:[547..555] sequence))
      (PP (IN:[556..558] of)
        (NP
          (NP (NN:[559..562] GA1))
          (CC:[563..566] and)
          (NP (JJ:[567..574] genomic)
            (NML (JJ:[575..583] Southern) (NN:[585..589] blot))
            (NN:[590..598] analysis)))))
    (VP (VBD:[599..608] indicated)
      (SBAR (IN:[609..613] that)
        (S
          (NP-SBJ-1 (NN:[614..617] GA1))
          (VP (VBZ:[618..620] is)
            (VP (VBN:[621..628] derived)
              (NP-1 (-NONE-:[628..628] *))
              (PP-CLR (IN:[629..633] from)
                (NP
                  (NP
                    (NML
                      (NML (JJ:[634..639] human) (NN:[640..649] papilloma)
                           (NN:[650..655] virus))
                      (NML (-LRB-:[656..657] -LRB-) (NN:[657..660] HPV)
                           (-RRB-:[660..661] -RRB-)))
                    (CD:[662..664] 18) (NN:[666..669] DNA))
                  (SBAR
                    (WHNP-2 (WDT:[670..674] that))
                    (S
                      (NP-SBJ-2 (-NONE-:[674..674] *T*))
                      (VP (VBD:[675..678] had)
                        (VP (VBN:[679..683] been)
                          (VP (VBN:[684..694] integrated)
                            (NP-2 (-NONE-:[694..694] *))
                            (PP (IN:[695..699] into)
                              (NP (DT:[700..703] the) (NN:[704..708] HeLa)
                                  (NN:[709..715] genome)))))))))))))))
    (.:[715..716] .)))

;sentence 7 Span:717..788
;The enhancer is located in  the non-coding region of the HPV 18 genome.
(SENT
  (S
    (NP-SBJ-1 (DT:[717..720] The) (NN:[721..729] enhancer))
    (VP (VBZ:[730..732] is)
      (VP (VBN:[733..740] located)
        (NP-1 (-NONE-:[740..740] *))
        (PP-LOC (IN:[741..743] in)
          (NP
            (NP (DT:[745..748] the)
              (ADJP (AFX:[749..752] non) (HYPH:[752..753] -)
                    (VBG:[753..759] coding))
              (NN:[760..766] region))
            (PP (IN:[767..769] of)
              (NP (DT:[770..773] the)
                (NML (NN:[774..777] HPV) (CD:[778..780] 18))
                (NN:[781..787] genome)))))))
    (.:[787..788] .)))

;sentence 8 Span:789..902
;The HPV 18 enhancer consists of two  functional domains, both of which have
;full enhancer activity in HeLa cells.
(SENT
  (S
    (NP-SBJ (DT:[789..792] The)
      (NML (NN:[793..796] HPV) (CD:[797..799] 18))
      (NN:[800..808] enhancer))
    (VP (VBZ:[809..817] consists)
      (PP-CLR (IN:[818..820] of)
        (NP (CD:[821..824] two) (JJ:[826..836] functional)
            (NNS:[837..844] domains)))
      (,:[844..845] ,)
      (SBAR
        (WHNP-1
          (NP (DT:[846..850] both))
          (WHPP (IN:[851..853] of)
            (WHNP (WDT:[854..859] which))))
        (S
          (NP-SBJ-1 (-NONE-:[859..859] *T*))
          (VP (VBP:[860..864] have)
            (NP (JJ:[865..869] full) (NN:[870..878] enhancer)
                (NN:[879..887] activity))
            (PP-LOC (IN:[888..890] in)
              (NP (NN:[891..895] HeLa) (NNS:[896..901] cells)))))))
    (.:[901..902] .)))

;sentence 9 Span:903..1015
;The  enhancer does not contain enhancer core sequences but contains several
;blocks of  potential Z-DNA sequence.
(SENT
  (S
    (NP-SBJ (DT:[903..906] The) (NN:[908..916] enhancer))
    (VP
      (VP (VBZ:[917..921] does) (RB:[922..925] not)
        (VP (VB:[926..933] contain)
          (NP (NN:[934..942] enhancer) (NN:[943..947] core)
              (NNS:[948..957] sequences))))
      (CC:[958..961] but)
      (VP (VBZ:[962..970] contains)
        (NP
          (NP (JJ:[971..978] several) (NNS:[979..985] blocks))
          (PP (IN:[986..988] of)
            (NP (JJ:[990..999] potential) (NN:[1000..1005] Z-DNA)
                (NN:[1006..1014] sequence))))))
    (.:[1014..1015] .)))

;sentence 10 Span:1016..1133
;Like SV40 and polyoma virus enhancers, the activity of  the HPV 18 enhancer
;was repressed by adenovirus E1a products.
(SENT
  (S
    (PP (IN:[1016..1020] Like)
      (NP
        (NP
          (NML (NN:[1021..1025] SV40)
            (NML-1 (-NONE-:[1025..1025] *P*)))
          (NML-2 (-NONE-:[1025..1025] *P*)))
        (CC:[1026..1029] and)
        (NP
          (NML (NN:[1030..1037] polyoma)
            (NML-1 (NN:[1038..1043] virus)))
          (NML-2 (NNS:[1044..1053] enhancers)))))
    (,:[1053..1054] ,)
    (NP-SBJ-3
      (NP (DT:[1055..1058] the) (NN:[1059..1067] activity))
      (PP (IN:[1068..1070] of)
        (NP (DT:[1072..1075] the)
          (NML (NN:[1076..1079] HPV) (CD:[1080..1082] 18))
          (NN:[1083..1091] enhancer))))
    (VP (VBD:[1092..1095] was)
      (VP (VBN:[1096..1105] repressed)
        (NP-3 (-NONE-:[1105..1105] *))
        (PP (IN:[1106..1108] by)
          (NP-LGS (NN:[1109..1119] adenovirus) (NN:[1120..1123] E1a)
                  (NNS:[1124..1132] products)))))
    (.:[1132..1133] .)))

;sentence 11 Span:1134..1325
;The HPV 18  enhancer shows a narrow cell type specificity: it is active in
;some cervical  carcinoma cell lines, but inactive in all non-cervical cells
;except for one  neuroblastoma cell line.
;[1214..1233]:malignancy-type:"cervical  carcinoma"
;[1301..1314]:malignancy-type:"neuroblastoma"
(SENT
  (S
    (S
      (NP-SBJ (DT:[1134..1137] The)
        (NML (NN:[1138..1141] HPV) (CD:[1142..1144] 18))
        (NN:[1146..1154] enhancer))
      (VP (VBZ:[1155..1160] shows)
        (NP (DT:[1161..1162] a) (JJ:[1163..1169] narrow)
          (NML (NN:[1170..1174] cell) (NN:[1175..1179] type))
          (NN:[1180..1191] specificity))))
    (::[1191..1192] :)
    (S
      (NP-SBJ (PRP:[1193..1195] it))
      (VP (VBZ:[1196..1198] is)
        (ADJP-PRD
          (ADJP (JJ:[1199..1205] active)
            (PP (IN:[1206..1208] in)
              (NP (DT:[1209..1213] some)
                 (JJ:[1214..1222] cervical) (NN:[1224..1233] carcinoma)
                (NN:[1234..1238] cell) (NNS:[1239..1244] lines))))
          (,:[1244..1245] ,) (CC:[1246..1249] but)
          (ADJP (JJ:[1250..1258] inactive)
            (PP-LOC (IN:[1259..1261] in)
              (NP
                (NP (DT:[1262..1265] all)
                  (ADJP (AFX:[1266..1269] non) (HYPH:[1269..1270] -)
                        (JJ:[1270..1278] cervical))
                  (NNS:[1279..1284] cells))
                (PP (IN:[1285..1291] except)
                  (PP (IN:[1292..1295] for)
                    (NP (CD:[1296..1299] one) (NN:[1301..1314] neuroblastoma)
                        (NN:[1315..1319] cell) (NN:[1320..1324] line))))))))))
    (.:[1324..1325] .)))

;sentence 12 Span:1326..1431
;These results suggest that the HPV 18 enhancer plays an  important role in
;regulation of the viral genes.
(SENT
  (S
    (NP-SBJ (DT:[1326..1331] These) (NNS:[1332..1339] results))
    (VP (VBP:[1340..1347] suggest)
      (SBAR (IN:[1348..1352] that)
        (S
          (NP-SBJ (DT:[1353..1356] the)
            (NML (NN:[1357..1360] HPV) (CD:[1361..1363] 18))
            (NN:[1364..1372] enhancer))
          (VP (VBZ:[1373..1378] plays)
            (NP (DT:[1379..1381] an) (JJ:[1383..1392] important)
                (NN:[1393..1397] role))
            (PP (IN:[1398..1400] in)
              (NP
                (NP (NN:[1401..1411] regulation))
                (PP (IN:[1412..1414] of)
                  (NP (DT:[1415..1418] the) (JJ:[1419..1424] viral)
                      (NNS:[1425..1430] genes)))))))))
    (.:[1430..1431] .)))

;section 13 Span:1435..1479
;PMID: 3038518 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1435..1439] PMID) (::[1439..1440] :) (CD:[1441..1448] 3038518)
        (NN:[1449..1450] -LSB-) (NNP:[1450..1456] PubMed) (::[1457..1458] -)
        (NN:[1459..1466] indexed) (IN:[1467..1470] for)
        (NNP:[1471..1478] MEDLINE) (-RRB-:[1478..1479] -RSB-)))
